Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $2.12
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 23, 26 | Evercore ISI Group |
| maintain |
| Outperform |
| Outperform |
| May 18, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 14, 26 | Citizens | maintain | Market Outperform | Market Outperform |
| Mar 16, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Mar 6, 26 | B. Riley Securities | maintain | Buy | Buy |
| Nov 7, 25 | Citizens | maintain | Market Outperform | Market Outperform |
| Oct 20, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Oct 10, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 13, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 23.21 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 7.18 | Oscillator | Buy |
| Williams %R (14) | -91.18 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.23 (Hist -0.03) | Oscillator | Strong Sell |
| Average Directional Index (14) | 38.47 (+DI 11.6 / -DI 35.4) | Trend | Strong Sell |
| EMA 20 | 2.49 | MA | Strong Sell |
| SMA 20 | 2.52 | MA | Strong Sell |
| EMA 50 | 2.76 | MA | Strong Sell |
| SMA 50 | 2.92 | MA | Strong Sell |
| SMA 200 | 3.33 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 1, 26 | Arbet-Engels Christophe | officer: Chief Medical Officer | M-Exempt | 37,500 | — |
| Oct 1, 26 | Arbet-Engels Christophe | officer: Chief Medical Officer | M-Exempt | 37,500 | — |
| Oct 1, 26 | Arbet-Engels Christophe | officer: Chief Medical Officer | F-InKind | 12,679 @ $2.76 | $34.99K |
| Oct 1, 26 | Weaver Gregory L | officer: Chief Financial Officer | M-Exempt | 14,475 | — |
| Oct 1, 26 | Weaver Gregory L | officer: Chief Financial Officer | F-InKind | 4,379 @ $2.76 | $12.09K |
| Oct 1, 26 | Weaver Gregory L | officer: Chief Financial Officer | M-Exempt | 14,475 | — |
| Oct 1, 26 | Menziuso Richard Thomas | officer: Principal Accounting Officer | A-Award | 84,546 @ $2.76 | $233.3K |
| Oct 1, 26 | Menziuso Richard Thomas | officer: Principal Accounting Officer | A-Award | 36,234 | — |
FY2021 · 10-K disclosure
TTM vs. 5-year historical average (annual ratios)
| Metric | ALT | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -2.7x | -5.8x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -3.6x | EPS est. -0.58 | Elevated |
| Price / Book | 0.8x | 2.9x | Discount |
| Price / Sales | 13302.5x | 4698.8x | Elevated |
| EV / EBITDA | -4.2x | -4.7x | In line |
| Return on equity | -31.4% | — | Weak |
| Gross margin | -48306.5% | 100.0% | Below hist. |
| Debt / Equity | 0.08 | 0.04 | Conservative |
| Piotroski / Altman Z | 2/9 | Z 2.98 | Grey zone |
Stock news · updated daily
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced initial results from the Company's Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an inves
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free surv
Discounted cash flow model
| 8-K | Sep 29, 2026 | 2026-09-29 07:03:49 | View |
| 4 | Sep 17, 2026 | 2026-09-17 16:05:29 | View |
| 4 | Aug 13, 2026 | 2026-08-13 16:05:06 | View |
| 10-Q | Aug 12, 2026 | 2026-08-12 16:04:09 | View |
| 8-K | Aug 12, 2026 | 2026-08-12 07:33:59 | View |
| 4 | Aug 3, 2026 | 2026-08-03 16:05:20 | View |
Proxy statement (DEF 14A) disclosures
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 11, 2026 | -0.14 | -0.12 | Beat 11.4% | — |
| May 13, 2026 | -0.25 | -0.18 | Beat 28.0% | — |
| Mar 5, 2026 | -0.25 | -0.27 | Miss -8.0% | $26.00K |
| Nov 6, 2025 | -0.29 | -0.21 | Beat 27.6% | $5.00K |
| Aug 12, 2025 | -0.32 | -0.27 | Beat 15.6% | $5.00K |
| May 13, 2025 | -0.35 | -0.26 | Beat 25.7% | $5.00K |